Loading...
Loading...
IMNM| Name | Value |
|---|---|
| Revenues | 2.4M |
| Cost of Revenue | 0.7M |
| Gross Profit | 1.7M |
| Operating Expense | 41.7M |
| Operating I/L | -40.0M |
| Other Income/Expense | 3.9M |
| Interest Income | 3.9M |
| Pretax | -36.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -36.1M |
Immunome, Inc. is a biopharmaceutical company specializing in the discovery and development of antibody therapeutics for oncology and infectious diseases. The company's lead oncology program, IMM-ONC-01, targets the IL-38 tumor-derived immune checkpoint to combat immune system evasion. Additionally, Immunome, Inc. is developing IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.
